GCL
CTOR

Glazer Capital LLC’s Citius Oncology CTOR Stock Holding History

Glazer Capital LLC’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-306,718
Closed -$3.48M – 155
2024
Q2 		$3.48M Sell
306,718
-4,569
-1% -$51.2K 0.27% 65
2024
Q1 		$3.44M Sell
311,287
-95,442
-23% -$1.05M 0.36% 59
2023
Q4 		$4.45M Sell
406,729
-4,819
-1% -$52.5K 0.46% 55
2023
Q3 		$4.43M Sell
411,548
-124
-0% -$1.32K 0.29% 65
2023
Q2 		$4.33M Hold
411,672
– – 0.29% 73
2023
Q1 		$4.26M Buy
411,672
+25,000
+6% +$257K 0.23% 105
2022
Q4 		$3.93M Buy
+386,672
New +$3.92M 0.1% 175

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Glazer Capital LLC's CTOR Position: Q3 2024 in Review

Glazer Capital LLC sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 306,718 shares — an estimated $3.48M sold.

Glazer Capital LLC first reported a position in CTOR in Q4 2022 and held it in 7 quarters. The position peaked at $4.45M in Q4 2023. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Glazer Capital LLC reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Glazer Capital LLC sold 306,718 Citius Oncology shares in Q3 2024, an estimated $3.48M.
  • Glazer Capital LLC first reported a position in Citius Oncology in Q4 2022 and held it in 7 quarters.
  • Glazer Capital LLC's Citius Oncology position peaked at $4.45M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Glazer Capital LLC's 13F filing for Q3 2024, filed 14 Nov 2024.